Research Analysts Offer Predictions for NRXP Q3 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Ascendiant Capital Markets lowered their Q3 2026 earnings per share (EPS) estimates for NRx Pharmaceuticals in a research report issued on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.15) per share for the quarter, down from their previous forecast of ($0.08). The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.80) per share. Ascendiant Capital Markets also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.35) EPS.

A number of other brokerages have also weighed in on NRXP. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th. Wall Street Zen cut shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, September 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NRXP opened at $2.94 on Tuesday. The firm has a market cap of $127.30 million, a P/E ratio of -5.35 and a beta of 2.07. The stock has a 50 day simple moving average of $3.29 and a two-hundred day simple moving average of $3.33. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. AdvisorShares Investments LLC increased its stake in shares of NRx Pharmaceuticals by 28.2% during the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after buying an additional 92,463 shares during the period. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals in the second quarter valued at $54,000. Finally, Ethos Financial Group LLC increased its position in NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after purchasing an additional 4,000 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: NRx Pharmaceuticals secured a $11.2 million DARPA contract to support a depression trial. The award provides non-dilutive funding for development of the company’s treatment program and may reduce near-term financing pressure. NRx secures DARPA contract for depression trial and $11.2 million award
• Neutral Sentiment: An analyst comparison examined NRx Pharmaceuticals alongside AstraZeneca, but the report provides no specific change to NRXP’s valuation, rating, or operating outlook. AstraZeneca and NRx Pharmaceuticals head-to-head review
• Negative Sentiment: Ascendiant Capital Markets lowered its earnings expectations across multiple periods. Its FY2026 EPS forecast fell to $(0.80) from $(0.36), while its FY2027 forecast dropped to $(0.35) from $0.50. Quarterly estimates were also reduced, including Q3 2026 to $(0.15) from $(0.08), Q4 2026 to $(0.17) from $(0.03), and Q2 2027 to $(0.13) from $0.05.
• Negative Sentiment: The analyst also cut its Q3 2027 estimate to $(0.10) from $0.17 and Q4 2027 to $0.05 from $0.28. The revisions indicate weaker-than-expected earnings prospects and could weigh on NRXP, particularly because the company remains loss-making and has historically reported limited revenue. Q3 EPS estimate for NRx Pharmaceuticals lowered by analyst

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations.

NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.